TAKE RAPAFLO® ONCE DAILY

For continued relief

Usually, your urologist or health care provider will prescribe an 8 mg dosage of RAPAFLO® to be taken once daily with a meal.2 However, RAPAFLO® comes in two different strengths, 8 mg and 4 mg. You should discuss any questions you have about how to take RAPAFLO® with your urologist.

BEFORE TAKING RAPAFLO®, MAKE SURE YOU SPEAK WITH YOUR UROLOGIST OR HEALTH CARE PROVIDER:
Cataract Surgery:
It’s important to let your urologist know if you’re planning to have cataract surgery2

You should also make sure your eye doctor knows if you are currently, or have ever taken RAPAFLO®, before having any procedures involving your eyes2
Liver or Kidney Issues: Men with severe liver or kidney problems should NOT take RAPAFLO®2
Low Blood Pressure: If you've ever had low blood pressure or signs of low blood pressure like fainting, dizziness, or light-headedness2
Other Medications: If you've taken certain antifungal drugs, any other alpha-blocker that treats high blood pressure or prostate problems, or HIV drugs called protease inhibitors2
RAPAFLO® is not for women or children.2
Do not take RAPAFLO® if you know you are allergic to it or any of its ingredients.
*Per 30-capsule supply. Offer expires 12/31/2014. Actavis reserves the right to rescind, revoke, or amend this offer without notice at any time.
  • COMMON QUESTIONS
    Is it better to take RAPAFLO® at night or in the morning?

    It is recommended to take RAPAFLO® along with a meal. However, you should talk to your urologist or health care provider about when he or she believes you should take RAPAFLO®.

    How do I ensure I get RAPAFLO® at the pharmacy?
  • REFERENCES
    1. National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: benign prostatic hyperplasia.
      NIH Publication No. 07-3012. June 2006.
    2. RAPAFLO® (silodosin) Capsules full Prescribing Information, Parsippany, NJ: Watson Pharma, Inc. January 2013.
    3. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634-2640.
    4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.
    5. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011;14:143-148.
    6. Shvartzman P, Borkan JM, Stoliar L, et al. Second-hand prostatism: effects of prostatic symptoms on spouses’ quality of life, daily routines and family relationships. Family Pract. 2001;18:610-613.
    7. Data on file, Watson Laboratories, Inc.
    8. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia:
      a 9-month, open-label extension study. Urology. 2009;74:1318-1322.
    9. Cunha, JP. Frequent urination. eMedicine Health from WebMD. Available at: http://www.emedicinehealth.com/frequent_urination/article_em.htm. Accessed April 22, 2013.
    10. Issa MM, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13:S4-S9.
    11. Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older.
      Am J Manag Care. 2006;12(4 suppl):S90-S98.
    12. American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
    13. Medline Plus Medical Encyclopedia from NIH: Enlarged prostate. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed July 29, 2010.
    14. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33:481-488.
    15. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1-adrenoceptor antagonists. BJU Int. 2005;95(Suppl 4):29-36.
    16. Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of an ejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med. 2008;5:2185-2190.
    17. Kaplan SA. Side effects of α-blocker use: retrograde ejaculation. Rev Urol. 2009;11(Suppl 1):S14-S18.
    18. JALYN (dutasteride and tamsulosin hydrochloride) Capsules full Prescribing Information, GlaxoSmithKline, October 2012.
    19. Rosen RC, Giuliano F, Cason CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824-837.
    20. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5:72-80.
    21. Kaplan S, Roehrborn CG, Hill LA, Volinn W. Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter? Open Access J Urol. 2011;3:89-93.
    22. American Urological Association Foundation. Prostate Health Playbook. AUA Foundation. 2011. Available at: http://www.urologyhealth.org/_media/_pdf/KYS%20Playbook%2012-11.pdf. Accessed May 17, 2013.
    23. Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.
      Int J Impot Res. 2007;19:544-550.
    24. Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):S42-S48.
    25. Wolters R, Wensing M, Van Weel C, Van Der Wilt GJ, Grol RPTM. Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int. 2002;90:655-661.

RAPAFLO® is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

RAPAFLO® is not indicated for the treatment of hypertension.

Important Safety Information

RAPAFLO® is available only by prescription and is approved to treat male urinary symptoms due to BPH, also called an enlarged prostate. RAPAFLO® should not be used to treat high blood pressure. Only your doctor can tell if you have BPH, not a more serious condition like prostate cancer. RAPAFLO® should not be used in patients with severe liver or kidney disease as well as those taking certain antifungal or HIV drugs. Do not take RAPAFLO® if you know you are allergic to it or any of its ingredients. Avoid driving or hazardous tasks until you know how RAPAFLO® will affect you, as a sudden drop in blood pressure may occur, rarely resulting in fainting. If considering cataract surgery, tell your eye surgeon you're currently taking RAPAFLO® or have taken it in the past. Side effects include a decrease or absence of semen during sex, dizziness, diarrhea, lightheadedness upon standing or sitting up abruptly, headache, swelling of the throat and nasal passages, and stuffy nose.

To report a side effect from one of our products, please call the Actavis Drug Safety Department at 1-800-272-5525.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

RAPAFLO® and its design are registered trademarks of Actavis, Inc.